viewFutura Medical PLC

Rep Boost for Futura Medical's Erectile Dysfunction gel

Sexual intimacy cures have been pedalled for centuries but science is now in the marketplace with, among others,  Futura Medical's (LON:FUM) MED2002 gel getting noticed in all the right places.The publication, The Journal of Sexual Medicine, is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel. CEO James Barder tells Proactive why he thinks MED2002 is superior to the two other main orally-taken competitors. James also updates us on the company's Clinical Development programme and progressing their Phase III pathway through 2018.

Quick facts: Futura Medical PLC

Price: 9.375 GBX

Market: AIM
Market Cap: £23.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Futura Medical CEO talks regulatory timeline and commercial potential for...

Futura Medical PLC's (LON:FUM)  James Barder caught up with Proactive London's Andrew Scott on the back of their 2019 results. He says the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third...

3 days, 3 hours ago

2 min read